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BACKGROUND MitraClip procedure is a valid alternative in high
surgical risk patients with severe mitral regurgitation (MR). Predictors
for an acute increase of cardiac output (CO) after MitraClip have not
been studied. We aim to analyze predictors for cardiac output (CO)
improvement.
METHODS From January 2014 to May 2015, 108 consecutive high
surgical risk patients with moderate or severe MR underwent mitral
valve repair with MitraClip device. CO before and after the procedure
was measured by thermo-dilution in all patients and an increase 25%
was deﬁned as relevant.
RESULTS Out of 108 patients (mean age 76  7 yrs, 69.4% male), 45
(42%) had an increase  25% of CO. Patients with CO increase  25%
signiﬁcantly more often presented with a residual MR  1þ (p¼0.01)
and had a lower baseline CO (2.9  0.7 vs 3.1  0.9, p¼0.082). Patients
with no relevant increase in CO had a higher rate of previous PCI (57%
vs 36%, p¼0.017) and of COPD (22% vs 7%, p¼0.024). Mean left ven-
tricular ejection fraction was similar in patients with compared to
without CO increase (44 vs 42%, p¼0.656). Binary logistic regression
analysis identiﬁed residual MR  1þ (p¼0.007), low baseline CO
(p¼0.048), absence of previous PCI (p¼0.034) and absence of COPD
(p¼0.026) as independent predictors for an increase  25% of CO.
CONCLUSIONS Acute CO improvement after MitraClip is not only
predicted by a good procedure outcome but also by patient’s comor-
bidity and baseline CO.
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BACKGROUND An estimated 4 million people in Europe and 4 million
people in the United States have signiﬁcant mitral valve insufﬁciency,
also known as mitral regurgitation, with an annual incidence of
250,000.1 Approximately 50,000 of these patients undergo surgery
each year.2 Mitral valve insufﬁciency, if left untreated, is associated
with chronic volume overload, which leads to heart muscle dysfunc-
tion, development of congestive heart failure (CHF) and thus
increased morbidity and mortality. Mitral valve regurgitation (MR) has
proven to increase the risk of mortality in patients with CHF, a disease
affecting more than 25 million worldwide. As MR worsens, so does
CHF and, hence, risk of mortality. Compared to CHF patients with no
MR, mild MR increases risk of mortality at 5 years by 18% and mod-
erate to severe MR by 53%.3 Treatment for MR is performed to better a
patient’s prognosis. Mitral valve repair is considered superior to mitral
valve replacement because of lower operative mortality, improved
late survival, a reduced risk of endocarditis, fewer thromboembolic
complications. 1,4,5,6,7,8 There is also a growing body of evidence
that supports early mitral valve repair instead of valve replacement
for signiﬁcant mitral regurgitation. Early beneﬁts of repair include
shorter hospital stays, less need for anticoagulant therapy, and low-
ered in-hospital mortality and complication rates.
METHODS It has been proposed two goals of treatment of patients for
FMR should be to slow or reverse LV remodeling and to improve the
patient’s symptoms or functional class.9 The Mitralign Percutaneous
Annuloplasty System, MPAS, for treating functional mitral regurgita-
tion is a novel device for percutaneous mitral valve repair. The
mechanism of treatment for the MPAS is to deliver pledgets to the
posterior mitral annulus and subsequently plicate (pull together) the
annulus to reduce annular circumference. (Figure 1) The Mitralign
MPAS study is a prospective, single-arm, multi-center, ﬁrst-in-human
study using the Mitralign MPAS and enrolled FMR patients including
those considered high risk for surgery. Patient demographics are
presented in Table 1. The Primary Safety Endpoint for the study is all
major adverse events (MAE) within 30 days post index procedure.MAE is deﬁned as occurrence of any of the following: Mitral valve
related cardiac surgery/intervention, myocardial infarction, cardiac
tamponade, stroke, or device/procedure-related death. The Primary
Performance Endpoint of this study is deﬁned as freedom from mitral
valve-related cardiac surgery/intervention, and freedom from device
and/or procedure-related death within 6 months; and freedom from
an increase in ventricular diameter at 6 months.
RESULTS At 30 days freedom from all-cause mortality was 92.2%. At
six months, the annular dimensions of the mitral valves were signif-
icantly reduced in both the A-P and S-L directions by -0.35  0.4 cm,
p< 0.01, and -0.32  0.3 cm, p< 0.01, respectively.
CONCLUSIONS The MPAS is safe/effective
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BACKGROUND The randomized PROTECT AF trial demonstrated
non–inferiority of left atrial appendage (LAA) closure to oral anti-
coagulation with warfarin. Current guidelines on the management of
atrial ﬁbrillation patients with high stroke risk and contraindications
for long-term oral anticoagulation give a class IIb recommendation for
LAA closure. Data on the efﬁcacy of LAA closure in patients at high
risk for ischemic stroke and bleeding events however are limited. We
evaluate the efﬁcacy and safety of LAA closure with the Amplatzer
cardiac plug (St. Jude Medical) or the Watchman LAA closure device
(Boston Scientiﬁc) in a consecutive series of high risk non-valvular
atrial ﬁbrillation patients with either contraindications to long-term
oral anticoagulation or at high bleeding risk.
METHODS A series of 101 consecutive non-valvular atrial ﬁbrillation
patients (age 74.7 7.5 years) at high risk for stroke (CHA2DS2- VASc
Score 4.41.6) and high bleeding risk (HAS-BLED Score 4.21.3)
received LAA closure with either the Watchman left atrial appendage
system (38 patients) or the Amplatzer cardiac plug (63 patients).
Average size of the LAA closure device was 25.03.7 mm (range 16-
33 mm). Dual antiplatelet therapy with aspirin 100 mg od and clopi-
dogrel 75mg od was recommended for the ﬁrst 3-6 month after device
implantation, followed by long-term antiplatelet therapy with aspirin
100mg od. No anticoagulation was recommended after device im-
plantation. Mean follow-up was 400 days. Transesophageal echocar-
diography was done 3 and 12 month after LAA closure.
RESULTS Procedure related serious complications were seen in 2
patients with pericardial tamponade, requiring pericardiocentesis.
One patient (1%) had a transient ischemic attack at day 299 post im-
plantation and two patients (2%) suffered from ischemic stroke (day 1
and day 398). Respectively, the expected annual stroke rate according
to CHA2DS2-VASc Score would have been 4.0 to 6.7%. While on rec-
ommended antiplatelet therapy bleeding occurred in 12/101 patients
(12%). The average HAS-BLED Score for these patients was 5.31.5
(range 4-7). During long-term follow-up after discontinuation of dual
antiplatelet therapy two additional bleeding events (2.4%) occurred.
In contrast the expected annual bleeding rate according to HAS-BLED
Score ranged between 8.7 to 12.5%.
CONCLUSIONS Left atrial appendage closure in patients with non-
valvular atrial ﬁbrillation and high risk for stroke and bleeding events
effectively prevented stroke and reduced cerebral ischemic events
compared to expected stroke rate according to CHA2DS2-VASc Score
